FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF FLOATING TABLETS OF LAFUTIDINE BY EMPLOYING EFFERVESCENT TECHNOLOGY
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 2
Abstract
In the present research work gastro retentive floating matrix formulation of Lafutidine by using various polymers were developed. Initially analytical method development was done for the drug molecule. Absorption maxima was determined based on that calibration curve was developed by using different concentrations. Gas generating agent sodium bicarbonate concentration was optimised. Then the formulation was developed by using different concentrations of polymers Xanthan gum, guar gum and Sodium Alginate as polymeric substances. The formulation blend was subjected to various pre-formulation studies, flow properties and all the formulations were found to be good indicating that the powder blend has good flow properties. Among all the formulations Only Xanthan gum, Sodium Alginate highest concentrations (60 mg) retards the drug release upto 12 hours and the drug release 96.25%, 95.81% respectively. In this Xanthan gum releases the more drug release when compared to Sodium alginate. So F3 Formulation considered as optimised formulation. Optimised formulation F3 was kept for release kinetic studies. From the above graphs it was evident that the formulation F3 was followed the Peppas release mechanism
Authors and Affiliations
Vageesh N. M, Ramya Sri Sura, K Gulijar Begum, Swathi B
Keywords
Related Articles
- EP ID EP326721
- DOI 10.22270/ijdra.v5i2.199
- Views 125
- Downloads 0
Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in different age groups of Patients in south east Rajasthan
Backgrounds: Elevated body triglycerides have been implicated as a risk factor of ischemic heart disease (IHD). Objectives: To study the association of serum triglyceride with ischemic heart disease and to assess the rel...
Registration of Drug Product dossier application as per EU Guidelines
Due to variations in the regulatory norms of registration dossier in different countries, there is a strong need for harmonization by ICH for approval of drugs. Generic drugs in EU are approved under the Marketing Author...
BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower d...
DIRECTION TO REACH CLOSER TO THE EFFECTIVE LABELING OF DRUGS WITH CRITICAL PARAMETERS
Labeling of drugs is an art of expressing information, instructions, caution or warning etc. in both word and pictorial form which must be readable without magnifying glass or visualizing aids. Font size and background o...
OVERVIEW OF DRUG REGULATORY AFFAIRS AND REGULATORY PROFESSION
Pharmaceutical drug regulatory affairs govern registration parameters of pharmaceutical products. It has a broad spectrum covering all aspects of documentation and marketing in legalized form. The pharmaceutical industry...